StockMarketWire.com - Verona Pharma said it would present positive symptom data from a trial of a treatment for chronic obstructive pulmonary disease at the American College of Chest Physicians annual meeting.

Chief medical officer Kathleen Rickard would expand on symptom data first announced by the company in March, where ensifentrine produced clinically and statistically significant improvements in lung function.


At 9:24am: [LON:VRP] Verona Pharma PLC share price was 0p at 48p



Story provided by StockMarketWire.com